IN BRIEF: Avacta says no fundraising imminent after market speculation

Mon, 19th Jun 2023 12:43

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months.

Current stock price: 104.75 pence, up 5.8% in London on Monday afternoon

12-month change: more than tripled from 28.99p

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Related Shares

More News

23 May 2024 21:25

TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

23 May 2024 12:09

Avacta reports further progress in chemotherapy trial

(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohor...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Latest Share Chat